Muscle tissue regeneration using muscle fiber fragments

Patent metadata

Field	Value
Publication number	US-9415076-B2
Application number	US-201214239416-A
Country	US
Kind code	B2
Filing date	Aug 15, 2012
Priority date	Aug 17, 2011
Publication date	Aug 16, 2016
Grant date	Aug 16, 2016

Abstract

The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and immunohistochemistry. This invention is particularly advantageous because autologous muscle can be harvested from a donor site, processed and injected into target sites in the operating room. The fragmented muscle fibers can be readily integrated within the host.

First claim

What is claimed is:

1. A composition comprising:
a population of muscle fiber fragments that are capable of reconstructing elongated muscle fibers from the fragments, and a scaffold,
wherein the fragments exhibit cell wall rupture and have an average size of less than 100 μm, and further wherein the composition further includes viable satellite cells associated with at least some of the fragments,
wherein the muscle fiber fragments are incorporated into the scaffold and
wherein the scaffold is an injectable scaffold selected from the group of collagen gel, fibrin gel, alginate gel, or UV-induced crosslinkable gel system.

2. The composition of claim 1 wherein the composition is capable of orienting in alignment with native muscle fibers when implanted in a target muscle site.

3. The composition of claim 1 , wherein the aspect ratio of the muscle fiber fragments is between 2:1 and 1:1.

4. The composition of claim 1 , wherein at least 75% of the muscle fiber fragments exhibit cell wall rupture.

5. The composition of claim 1 wherein the composition further comprises a physiologically compatible fluid and the composition is formulated for injection.

6. The composition of claim 1 wherein the composition further comprises an adjuvant.

7. The composition of claim 6 wherein the adjuvant comprises at least one agent selected from the group of stem cells, muscle progenitor cells and growth factors.

8. The composition of claim 6 wherein the adjuvant comprises muscle progenitor cells.

9. The composition of claim 6 wherein the adjuvant comprises at least one growth factor selected from the group of: a bone morphogenic protein (BMP), a RUNX-2 protein, a LIM mineralization protein, a fibroblast growth factor, a platelet derived growth factor, an epidermal growth factor, an insulin-like growth factor, a transforming growth factor-a, a transforming growth factor-β, a nerve growth factor (NGF), a brain-derived neurotrophic factor (BDNF), a neuregulin (NRG), and agrin.

10. The composition of claim 1 wherein the injectable scaffold comprises a collagen gel.

11. The composition of claim 1 wherein the injectable scaffold comprises a fibrin gel.

12. The composition of claim 1 wherein the injectable scaffold comprises an alginate gel.

13. The composition of claim 1 wherein the injectable scaffold comprises a UV-induced crosslinkable gel system.

Assignees

• Atala Anthony
• Yoo James
• Ko In Kap
• Univ Wake Forest Health Sciences

Inventors

• Atala Anthony
• Yoo James
• Ko In Kap

Classifications

• C12N2513/00

  3D culture · CPC title

• A61P13/02

  of urine or of the urinary tract, e.g. urine acidifiers · CPC title

• A61K9/0034

  Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants · CPC title

• A61L2300/414

  Growth factors · CPC title

• A61L27/3834

  Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells · CPC title